PT  - JOURNAL ARTICLE
AU  - Kishan, Amar U.
AU  - Siva, Shankar
AU  - Hofman, Michael S.
AU  - Nagarajah, James
AU  - Kiess, Ana P.
AU  - Tran, Phuoc
AU  - Calais, Jeremie
TI  - The Potential Contribution of Radiopharmaceutical Therapies in Managing Oligometastatic Disease
AID  - 10.2967/jnumed.123.266772
DP  - 2024 Apr 01
TA  - Journal of Nuclear Medicine
PG  - 502--509
VI  - 65
IP  - 4
4099  - http://jnm.snmjournals.org/content/65/4/502.short
4100  - http://jnm.snmjournals.org/content/65/4/502.full
SO  - J Nucl Med2024 Apr 01; 65
AB  - There is a growing understanding of the oligometastatic disease state, characterized by the presence of 5 or fewer lesions. Advanced molecular imaging techniques, such as prostate-specific membrane antigen PET, refines the ability to detect oligometastatic recurrences (oligorecurrences) early. These developments have led to the exploration of metastasis-directed therapy (MDT) in oligorecurrent disease as an alternative to or as a means of delaying systemic therapy. Unfortunately, MDT often does not provide a durable cure, and progression—particularly progression in multiple new areas—remains a concern. Simultaneously, developments in radioligand therapy (RLT) have led to studies showing overall survival benefits with α-emitting and β-emitting RLT in advanced, high-volume, metastatic castration-resistant prostate cancer. The success of RLT in late-stage disease suggests that earlier use in the disease spectrum may be impactful. Specifically, integration of RLT with MDT might reduce progression, including polymetastatic progression, in the setting of oligorecurrent disease.